Evobrutinib is a selective inhibitor of Bruton's tyrosine kinase (BTK) that is being developed as a potential treatment for multiple sclerosis. During the manufacturing process of Evobrutinib, impurities can be formed that may affect the quality, safety, and efficacy of the drug product. Therefore, identifying, characterizing and controlling these impurities is critical to ensure the drug's quality and safety. Various analytical techniques such as High-performance liquid chromatography (HPLC
